ArticleBreast cancer research : BCR2025
A STAT1-GBP1 axis modulates epithelial proliferation in postpartum breast tissue by repressing CDKI expression.
Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dynamics, function, and regulation of mammary stem cells in development and disease.Experimental & molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundPostpartum breast cancer, diagnosed within five years of childbirth, is associated with heightened mortality compared to breast cancers in nulliparous women. Although the postpartum breast undergoes extensive involution and remodeling, the molecular drivers that promote subsequent tumor development remain incompletely understood. We investigated whether signal transducer and activator of transcription 1 (STAT1) and guanylate binding protein 1 (GBP1) contribute to epithelial proliferation through suppression of cyclin-dependent kinase inhibitors (CDKIs).
methodsFormalin-fixed, paraffin-embedded postpartum (n = 5) and nulliparous (n = 5) benign breast tissues were profiled using transcriptomic panels targeting oncogenic and immunologic pathways. Protein expression of STAT1, GBP1, and the proliferation marker Ki67 was examined by immunohistochemistry. Functional studies were performed in human mammary epithelial cells (HMECs) derived from the same postpartum and nulliparous tissues. Small interfering RNA (siRNA) and lentiviral knockdown strategies were used to reduce STAT1 and GBP1, followed by assessment of CDKI expression, cell cycle distribution, and cell proliferation.
resultsTranscriptomic profiling revealed a postpartumspecific interferon signature (STAT1, GBP1), elevated Ki67, and reduced CDKIs; immunofluorescence across > 200 lobules confirmed these increases and suggested that GBP1 fully mediates the STAT1-Ki67 link. In HMECs, knockdown of STAT1 or GBP1 induced a marked rise in p21 and p57 (CDKN1A and CDKN1C), accompanied by G1 cell cycle arrest and reduced proliferation. Combined knockdown had an additive effect on suppressing epithelial proliferation, suggesting a cooperative role for STAT1 and GBP1 in modulating cell cycle progression.
conclusionsThese findings identify a STAT1-GBP1 axis that enhances postpartum epithelial proliferation by repressing CDKI expression. This mechanism may help to explain the heightened vulnerability observed after childbirth and highlights potential biomarkers or early intervention targets in postpartum breast tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.